In order to normalize and institutionalize the centralized procurement of drugs, in accordance with the deployment of the National Medical Insurance Bureau, led by the Hubei Provincial Medical Insurance Bureau, 30 provinces (autonomous regions, municipalities) including Beijing, Shanghai, and Guangdong formed a national procurement alliance to carry out Centralized procurement of Chinese patent medicines and related medicines.
The average decline rate of the selected varieties is 49.36%
A few days ago, the National Chinese Patent Medicine Alliance announced the results of the proposed selection in Hubei in centralized procurement. 63 companies and 68 quotation representative products were selected. The selection rate reached 71.6%, and the average price reduction of the selected varieties was 49.36%. This time, 15 varieties such as Fufang Xueshuantong and Guanxinning were selected. The selected products have complete dosage forms and specifications, and most of the mainstream products currently used in clinical practice are selected, which can effectively meet the needs of clinical medication. From the perspective of drug use, it involves 6 therapeutic fields of internal medicine, orthopedics, ophthalmology, tumor, cardiovascular system and gynecology. According to the calculation of the annual purchase amount in the alliance of 30 provinces (autonomous regions, municipalities), it is estimated that more than 4.5 billion yuan in drug costs can be saved each year, and the drug burden of patients is expected to be further reduced.
Experts said that after the implementation of the national centralized procurement of Chinese patent medicines, in addition to reducing the prices of selected medicines, it can also drive down the prices of Chinese patent medicines that have similar curative effects but have not been included in the centralized procurement.
Multi-group bidding for exclusive varieties of Chinese patent medicines ensures fairness
This centralized procurement follows the national centralized procurement of chemical drugs, biological drugs, and medical consumables. The centralized procurement also adjusted the policy according to the market structure of Chinese patent medicines, and adopted the method of group bidding of large and small enterprises for each kind of Chinese patent medicines.
The scale of Chinese patent medicine companies presents a trend of polarization. The number of leading companies is small, but the scale is huge, and the number of tail companies is large, but their market share is very small. In view of this characteristic of the Chinese patent medicine market, the Chinese patent medicine alliance has collected 16 varieties, and each procurement group is divided into two competitive units, A and B, to compete separately to ensure fairness and reasonableness.
Comprehensive scoring to determine the selected patent medicine
The production of Chinese patent medicines is subject to multiple influences from raw material origins, natural environment and other conditions. Minor formula differences may lead to different products. Therefore, there are many exclusive varieties and it is difficult to negotiate prices. The selection rules for this collective purchase comprehensively consider various factors including price to jointly determine the selected products.
Since the "consistency evaluation" of Chinese patent medicines similar to chemical medicines has not yet been carried out, the centralized procurement of Chinese patent medicines does not adopt "the lowest price wins" like chemical medicines, but uses a comprehensive score, including price, medical treatment Indicators such as institutional recognition, innovation capability, quality of medicinal materials, supply guarantee, etc.
Cui Dan, a researcher at the Global Health Research Center of Wuhan University: In addition to the price tag, a comprehensive score is made based on the scale and reputation of the company, whether it has won awards, innovation, social evaluation, etc., which is The total score of the two determines whether it can participate in the second round of quotations. That is to say, through the first round of comprehensive evaluation, we screen out some enterprises with particularly small scale and poor social reputation, which is a way for us to ensure quality.
微信扫一扫打赏
